Systemic chemotherapy for testicular cancer

Brian P. Mulherin, Noah M. Hahn, Lawrence H. Einhorn

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Testicular cancer is an uncommon malignancy, accounting for about 1% of all cancers in men. However, it represents the most common solid neoplasm in young adult males. Germ cell tumors are one of the most curable of all neoplasms, even in the metastatic setting. They are extremely sensitive to cisplatin-based combination chemotherapy, and surgical resection of residual disease has been shown to improve outcomes further. By combining chemotherapy, surgery, and sometimes radiotherapy, the vast majority of patients can now be cured. Testicular cancer has become a model for a curable neoplasm.

Original languageEnglish (US)
Title of host publicationEssentials and Updates in Urologic Oncology (2 Volume Set)
PublisherNova Science Publishers, Inc.
Pages607-630
Number of pages24
ISBN (Print)9781620816493
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Systemic chemotherapy for testicular cancer'. Together they form a unique fingerprint.

  • Cite this

    Mulherin, B. P., Hahn, N. M., & Einhorn, L. H. (2012). Systemic chemotherapy for testicular cancer. In Essentials and Updates in Urologic Oncology (2 Volume Set) (pp. 607-630). Nova Science Publishers, Inc..